-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on March 3
The fourth batch of national procurement, the implementation time is set
On March 2, the Liaoning Provincial Medical Insurance Bureau issued the "Notice on Preparing for the Implementation of the Fourth Batch of State-Organized Drug Centralized Procurement (Liaoning).
"
"
According to the notice, Liaoning Province will implement the fourth batch of the results of the Liaoning region's selection of national centralized mining from 0:00 on May 1.
The notification also requires:
Before March 20, it is necessary to complete the results of the selection and the announcement of the supplementary online publication of the drugs in the list of products supplied after the selection.
If the procurement is not online in Liaoning Province, relevant enterprises are requested to respond in a timely manner and complete related work on time.
If the procurement is not online in Liaoning Province, relevant enterprises are requested to respond in a timely manner and complete related work on time.
Before March 31st, the selected companies should establish a distribution relationship on the platform independently based on the principle of one distribution company for each prefecture-level city of one selected drug.
Before April 20th, the municipal medical insurance bureaus will organize medical institutions to complete the signing of bulk purchase contracts for drug production (business) enterprises.
Before April 20th, the medical insurance agencies of each city shall calculate the prepaid working capital according to the agreed purchase amount of the medical institution (the prepaid working capital shall be allocated to the medical institution in areas where the direct settlement of the medical insurance fund is not implemented).
Before April 30, the relevant selected drugs will be prepared in advance to the relevant medical institutions.
The implementation time of the fourth batch of national selection results is currently a work of great concern to the industry.
At present, various provinces have successively issued notices to carry out the declaration of net-linked varieties.
Liaoning has made it clear that May 1 is the official implementation time, and I believe that the implementation time arrangements in various places will not be too far from Liaoning.
At present, various provinces have successively issued notices to carry out the declaration of net-linked varieties.
Liaoning has made it clear that May 1 is the official implementation time, and I believe that the implementation time arrangements in various places will not be too far from Liaoning.
The price of a batch of medicines is greatly reduced, saving 12.
4 billion yuan every year
4 billion yuan every year
The data shows that the fourth batch of national procurement has selected 45 varieties and 80 product specifications, and the highest purchase scale exceeds 25 billion yuan.
It is estimated that 12.
4 billion yuan will be saved in drug costs each year.
It is estimated that 12.
4 billion yuan will be saved in drug costs each year.
Among them, the cost of a batch of commonly used drugs and anti-cancer drugs will be significantly reduced.
Among the commonly used drugs, such as the drug esomeprazole enteric-coated tablets (20mg/tablet) for the treatment of gastric ulcers, the price of each tablet will be reduced from 9 yuan to 3 yuan after the collection, and the entire course of treatment can save costs.
About 240 yuan; among the anti-cancer drugs, taking bortezomib injection for the treatment of multiple myeloma as an example, the price of a single dose has been reduced from 1,500 yuan to 600 yuan, and the entire course of treatment can save patients about 36,000 yuan.
Among the commonly used drugs, such as the drug esomeprazole enteric-coated tablets (20mg/tablet) for the treatment of gastric ulcers, the price of each tablet will be reduced from 9 yuan to 3 yuan after the collection, and the entire course of treatment can save costs.
About 240 yuan; among the anti-cancer drugs, taking bortezomib injection for the treatment of multiple myeloma as an example, the price of a single dose has been reduced from 1,500 yuan to 600 yuan, and the entire course of treatment can save patients about 36,000 yuan.
The head of the Pharmaceutical Price and pharmnet.
com.
cn/news/yyzb/" target="_blank">Bidding pharmnet.
com.
cn/news/yyzb/" target="_blank">Purchasing Department of the National Medical Insurance Bureau previously stated that compared with the third batch of national drug collections, the fourth batch of drug collections further fine-tuned and optimized the procurement rules, increasing the number of companies that can be selected from the original 8 to 10 companies to further improve their supply guarantee capabilities.
com.
cn/news/yyzb/" target="_blank">Bidding pharmnet.
com.
cn/news/yyzb/" target="_blank">Purchasing Department of the National Medical Insurance Bureau previously stated that compared with the third batch of national drug collections, the fourth batch of drug collections further fine-tuned and optimized the procurement rules, increasing the number of companies that can be selected from the original 8 to 10 companies to further improve their supply guarantee capabilities.
From the perspective of price reductions, after the implementation of the fourth batch of national procurement results, the market structure will undergo some changes.
1.
Decline in market size.
Some varieties that had high sales and took up a lot of medical insurance funds, after experiencing significant price cuts in centralized procurement, although the purchase volume may increase, the total sales may decline sharply.
This situation has been seen in the previous batches of national procurement.
Many examples.
Decline in market size.
Some varieties that had high sales and took up a lot of medical insurance funds, after experiencing significant price cuts in centralized procurement, although the purchase volume may increase, the total sales may decline sharply.
This situation has been seen in the previous batches of national procurement.
Many examples.
2.
Accelerate the replacement of original research by generic drugs.
For some original research drugs, due to the late launch of domestic generic drugs, coupled with the domestic academic promotion of the original research drugs and the comparison of patient education, the original research drugs have always occupied a leading position in the market.
However, in recent batches of centralized procurement, most foreign companies have chosen to abandon national centralized procurement.
Only two foreign companies won the bid in the 4+7 pilot program.
The 4+7 expansion increased by 5 and only 7 foreign companies won the bid.
In the second batch, only 4 foreign companies won the bid.
Foreign companies won the bid, only 3 pharmaceutical companies won the bid for the third batch, and only 5 foreign companies won the bid for the latest fourth batch.
With the advancement of national centralized procurement, it will further accelerate the replacement of original research by generic drugs.
Accelerate the replacement of original research by generic drugs.
For some original research drugs, due to the late launch of domestic generic drugs, coupled with the domestic academic promotion of the original research drugs and the comparison of patient education, the original research drugs have always occupied a leading position in the market.
However, in recent batches of centralized procurement, most foreign companies have chosen to abandon national centralized procurement.
Only two foreign companies won the bid in the 4+7 pilot program.
The 4+7 expansion increased by 5 and only 7 foreign companies won the bid.
In the second batch, only 4 foreign companies won the bid.
Foreign companies won the bid, only 3 pharmaceutical companies won the bid for the third batch, and only 5 foreign companies won the bid for the latest fourth batch.
With the advancement of national centralized procurement, it will further accelerate the replacement of original research by generic drugs.
3.
Speed up the process of consistency evaluation.
Judging from the current speed of national centralized procurement, it far exceeds industry expectations.
In the future, the national centralized procurement will involve more varieties of generic drugs through consistent evaluation.
In this process, those companies that have been reviewed with too many varieties, and the remaining companies that have not been reviewed may choose to abandon the market.
At the same time, some companies that are late to market and have weaker capital capabilities may also choose to give up the consistency evaluation.
Speed up the process of consistency evaluation.
Judging from the current speed of national centralized procurement, it far exceeds industry expectations.
In the future, the national centralized procurement will involve more varieties of generic drugs through consistent evaluation.
In this process, those companies that have been reviewed with too many varieties, and the remaining companies that have not been reviewed may choose to abandon the market.
At the same time, some companies that are late to market and have weaker capital capabilities may also choose to give up the consistency evaluation.
Medical Network News on March 3
The fourth batch of national procurement, the implementation time is set
On March 2, the Liaoning Provincial Medical Insurance Bureau issued the "Notice on Preparing for the Implementation of the Fourth Batch of State-Organized Drug Centralized Procurement (Liaoning).
"
"
According to the notice, Liaoning Province will implement the fourth batch of the results of the Liaoning region's selection of national centralized mining from 0:00 on May 1.
The notification also requires:
Before March 20, it is necessary to complete the results of the selection and the announcement of the supplementary online publication of the drugs in the list of products supplied after the selection.
If the procurement is not online in Liaoning Province, relevant enterprises are requested to respond in a timely manner and complete related work on time.
If the procurement is not online in Liaoning Province, relevant enterprises are requested to respond in a timely manner and complete related work on time.
Before March 31st, the selected companies should establish a distribution relationship on the platform independently based on the principle of one distribution company for each prefecture-level city of one selected drug.
Before April 20th, the municipal medical insurance bureaus will organize medical institutions to complete the signing of bulk purchase contracts for drug production (business) enterprises.
Before April 20th, the medical insurance agencies of each city shall calculate the prepaid working capital according to the agreed purchase amount of the medical institution (the prepaid working capital shall be allocated to the medical institution in areas where the direct settlement of the medical insurance fund is not implemented).
Before April 30, the relevant selected drugs will be prepared in advance to the relevant medical institutions.
The implementation time of the fourth batch of national selection results is currently a work of great concern to the industry.
At present, various provinces have successively issued notices to carry out the declaration of net-linked varieties.
Liaoning has made it clear that May 1 is the official implementation time, and I believe that the implementation time arrangements in various places will not be too far from Liaoning.
At present, various provinces have successively issued notices to carry out the declaration of net-linked varieties.
Liaoning has made it clear that May 1 is the official implementation time, and I believe that the implementation time arrangements in various places will not be too far from Liaoning.
The price of a batch of medicines is greatly reduced, saving 12.
4 billion yuan every year
4 billion yuan every year
The data shows that the fourth batch of national procurement has selected 45 varieties and 80 product specifications, and the highest purchase scale exceeds 25 billion yuan.
It is estimated that 12.
4 billion yuan will be saved in drug costs each year.
It is estimated that 12.
4 billion yuan will be saved in drug costs each year.
Among them, the cost of a batch of commonly used drugs and anti-cancer drugs will be significantly reduced.
Among the commonly used drugs, such as the drug esomeprazole enteric-coated tablets (20mg/tablet) for the treatment of gastric ulcers, the price of each tablet will be reduced from 9 yuan to 3 yuan after the collection, and the entire course of treatment can save costs.
About 240 yuan; among the anti-cancer drugs, taking bortezomib injection for the treatment of multiple myeloma as an example, the price of a single dose has been reduced from 1,500 yuan to 600 yuan, and the entire course of treatment can save patients about 36,000 yuan.
Among the commonly used drugs, such as the drug esomeprazole enteric-coated tablets (20mg/tablet) for the treatment of gastric ulcers, the price of each tablet will be reduced from 9 yuan to 3 yuan after the collection, and the entire course of treatment can save costs.
About 240 yuan; among the anti-cancer drugs, taking bortezomib injection for the treatment of multiple myeloma as an example, the price of a single dose has been reduced from 1,500 yuan to 600 yuan, and the entire course of treatment can save patients about 36,000 yuan.
The head of the Pharmaceutical Price and pharmnet.
com.
cn/news/yyzb/" target="_blank">Bidding pharmnet.
com.
cn/news/yyzb/" target="_blank">Purchasing Department of the National Medical Insurance Bureau previously stated that compared with the third batch of national drug collections, the fourth batch of drug collections further fine-tuned and optimized the procurement rules, increasing the number of companies that can be selected from the original 8 to 10 companies to further improve their supply guarantee capabilities.
com.
cn/news/yyzb/" target="_blank">Bidding pharmnet.
com.
cn/news/yyzb/" target="_blank">Purchasing Department of the National Medical Insurance Bureau previously stated that compared with the third batch of national drug collections, the fourth batch of drug collections further fine-tuned and optimized the procurement rules, increasing the number of companies that can be selected from the original 8 to 10 companies to further improve their supply guarantee capabilities.
From the perspective of price reductions, after the implementation of the fourth batch of national procurement results, the market structure will undergo some changes.
1.
Decline in market size.
Some varieties that had high sales and took up a lot of medical insurance funds, after experiencing significant price cuts in centralized procurement, although the purchase volume may increase, the total sales may decline sharply.
This situation has been seen in the previous batches of national procurement.
Many examples.
Decline in market size.
Some varieties that had high sales and took up a lot of medical insurance funds, after experiencing significant price cuts in centralized procurement, although the purchase volume may increase, the total sales may decline sharply.
This situation has been seen in the previous batches of national procurement.
Many examples.
2.
Accelerate the replacement of original research by generic drugs.
For some original research drugs, due to the late launch of domestic generic drugs, coupled with the domestic academic promotion of the original research drugs and the comparison of patient education, the original research drugs have always occupied a leading position in the market.
However, in recent batches of centralized procurement, most foreign companies have chosen to abandon national centralized procurement.
Only two foreign companies won the bid in the 4+7 pilot program.
The 4+7 expansion increased by 5 and only 7 foreign companies won the bid.
In the second batch, only 4 foreign companies won the bid.
Foreign companies won the bid, only 3 pharmaceutical companies won the bid for the third batch, and only 5 foreign companies won the bid for the latest fourth batch.
With the advancement of national centralized procurement, it will further accelerate the replacement of original research by generic drugs.
Accelerate the replacement of original research by generic drugs.
For some original research drugs, due to the late launch of domestic generic drugs, coupled with the domestic academic promotion of the original research drugs and the comparison of patient education, the original research drugs have always occupied a leading position in the market.
However, in recent batches of centralized procurement, most foreign companies have chosen to abandon national centralized procurement.
Only two foreign companies won the bid in the 4+7 pilot program.
The 4+7 expansion increased by 5 and only 7 foreign companies won the bid.
In the second batch, only 4 foreign companies won the bid.
Foreign companies won the bid, only 3 pharmaceutical companies won the bid for the third batch, and only 5 foreign companies won the bid for the latest fourth batch.
With the advancement of national centralized procurement, it will further accelerate the replacement of original research by generic drugs.
3.
Speed up the process of consistency evaluation.
Judging from the current speed of national centralized procurement, it far exceeds industry expectations.
In the future, the national centralized procurement will involve more varieties of generic drugs through consistent evaluation.
In this process, those companies that have been reviewed with too many varieties, and the remaining companies that have not been reviewed may choose to abandon the market.
At the same time, some companies that are late to market and have weaker capital capabilities may also choose to give up the consistency evaluation.
Speed up the process of consistency evaluation.
Judging from the current speed of national centralized procurement, it far exceeds industry expectations.
In the future, the national centralized procurement will involve more varieties of generic drugs through consistent evaluation.
In this process, those companies that have been reviewed with too many varieties, and the remaining companies that have not been reviewed may choose to abandon the market.
At the same time, some companies that are late to market and have weaker capital capabilities may also choose to give up the consistency evaluation.
Medical Network News on March 3
The fourth batch of national procurement, the implementation time is set
The fourth batch of national procurement, the implementation time is set On March 2, the Liaoning Provincial Medical Insurance Bureau issued the "Notice on Preparing for the Implementation of the Fourth Batch of State-Organized Drug Centralized Procurement (Liaoning).
"
Medicine, medicine, medicine"
According to the notice, Liaoning Province will implement the fourth batch of the results of the Liaoning region's selection of national centralized mining from 0:00 on May 1.
The notification also requires:
Before March 20, it is necessary to complete the results of the selection and the announcement of the supplementary online publication of the drugs in the list of products supplied after the selection.
If the procurement is not online in Liaoning Province, relevant enterprises are requested to respond in a timely manner and complete related work on time.
If the procurement is not online in Liaoning Province, relevant enterprises are requested to respond in a timely manner and complete related work on time.
Before March 31st, the selected companies should establish a distribution relationship on the platform independently based on the principle of one distribution company for each prefecture-level city of one selected drug.
Before April 20th, the municipal medical insurance bureaus will organize medical institutions to complete the signing of bulk purchase contracts for drug production (business) enterprises.
Before April 20th, the medical insurance agencies of each city shall calculate the prepaid working capital according to the agreed purchase amount of the medical institution (the prepaid working capital shall be allocated to the medical institution in areas where the direct settlement of the medical insurance fund is not implemented).
Before April 30, the relevant selected drugs will be prepared in advance to the relevant medical institutions.
The implementation time of the fourth batch of national selection results is currently a work of great concern to the industry.
At present, various provinces have successively issued notices to carry out the declaration of net-linked varieties.
Liaoning has made it clear that May 1 is the official implementation time, and I believe that the implementation time arrangements in various places will not be too far from Liaoning.
At present, various provinces have successively issued notices to carry out the declaration of net-linked varieties.
Liaoning has made it clear that May 1 is the official implementation time, and I believe that the implementation time arrangements in various places will not be too far from Liaoning.
The price of a batch of medicines is greatly reduced, saving 12.
4 billion yuan every year
4 billion yuan every year
The data shows that the fourth batch of national procurement has selected 45 varieties and 80 product specifications, and the highest purchase scale exceeds 25 billion yuan.
It is estimated that 12.
4 billion yuan will be saved in drug costs each year.
It is estimated that 12.
4 billion yuan will be saved in drug costs each year.
Among them, the cost of a batch of commonly used drugs and anti-cancer drugs will be significantly reduced.
Among the commonly used drugs, such as the drug esomeprazole enteric-coated tablets (20mg/tablet) for the treatment of gastric ulcers, the price of each tablet will be reduced from 9 yuan to 3 yuan after the collection, and the entire course of treatment can save costs.
About 240 yuan; among the anti-cancer drugs, taking bortezomib injection for the treatment of multiple myeloma as an example, the price of a single dose has been reduced from 1,500 yuan to 600 yuan, and the entire course of treatment can save patients about 36,000 yuan.
Among the commonly used drugs, such as the drug esomeprazole enteric-coated tablets (20mg/tablet) for the treatment of gastric ulcers, the price of each tablet will be reduced from 9 yuan to 3 yuan after the collection, and the entire course of treatment can save costs.
About 240 yuan; among the anti-cancer drugs, taking bortezomib injection for the treatment of multiple myeloma as an example, the price of a single dose has been reduced from 1,500 yuan to 600 yuan, and the entire course of treatment can save patients about 36,000 yuan.
The head of the Pharmaceutical Price and pharmnet.
com.
cn/news/yyzb/" target="_blank">Bidding pharmnet.
com.
cn/news/yyzb/" target="_blank">Purchasing Department of the National Medical Insurance Bureau previously stated that compared with the third batch of national drug collections, the fourth batch of drug collections further fine-tuned and optimized the procurement rules, increasing the number of companies that can be selected from the original 8 to 10 companies to further improve their supply guarantee capabilities.
Pharmaceutical medicine pharmaceuticalpharmnet. com.
cn/news/yyzb/" target="_blank">Bidding pharmnet.
com.
cn/news/yyzb/" target="_blank">Purchasing Department of the National Medical Insurance Bureau previously stated that compared with the third batch of national drug collections, the fourth batch of drug collections further fine-tuned and optimized the procurement rules, increasing the number of companies that can be selected from the original 8 to 10 companies to further improve their supply guarantee capabilities.
com.
cn/news/yyzb/" target="_blank"> tender pharmnet.
com.
cn/news/yyzb/" target="_blank">procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> tender biddingpharmnet.
com.
cn/news/yyzb/" target="_blank"> procurement procurement enterprise business enterprise
From the perspective of price reductions, after the implementation of the fourth batch of national procurement results, the market structure will undergo some changes.
1.
Decline in market size.
Some varieties that had high sales and took up a lot of medical insurance funds, after experiencing significant price cuts in centralized procurement, although the purchase volume may increase, the total sales may decline sharply.
This situation has been seen in the previous batches of national procurement.
Many examples.
Decline in market size.
Some varieties that had high sales and took up a lot of medical insurance funds, after experiencing significant price cuts in centralized procurement, although the purchase volume may increase, the total sales may decline sharply.
This situation has been seen in the previous batches of national procurement.
Many examples.
2.
Accelerate the replacement of original research by generic drugs.
For some original research drugs, due to the late launch of domestic generic drugs, coupled with the domestic academic promotion of the original research drugs and the comparison of patient education, the original research drugs have always occupied a leading position in the market.
However, in recent batches of centralized procurement, most foreign companies have chosen to abandon national centralized procurement.
Only two foreign companies won the bid in the 4+7 pilot program.
The 4+7 expansion increased by 5 and only 7 foreign companies won the bid.
In the second batch, only 4 foreign companies won the bid.
Foreign companies won the bid, only 3 pharmaceutical companies won the bid for the third batch, and only 5 foreign companies won the bid for the latest fourth batch.
With the advancement of national centralized procurement, it will further accelerate the replacement of original research by generic drugs.
Accelerate the replacement of original research by generic drugs.
For some original research drugs, due to the late launch of domestic generic drugs, coupled with the domestic academic promotion of the original research drugs and the comparison of patient education, the original research drugs have always occupied a leading position in the market.
However, in recent batches of centralized procurement, most foreign companies have chosen to abandon national centralized procurement.
Only two foreign companies won the bid in the 4+7 pilot program.
The 4+7 expansion increased by 5 and only 7 foreign companies won the bid.
In the second batch, only 4 foreign companies won the bid.
Foreign companies won the bid, only 3 pharmaceutical companies won the bid for the third batch, and only 5 foreign companies won the bid for the latest fourth batch.
With the advancement of national centralized procurement, it will further accelerate the replacement of original research by generic drugs.
3.
Speed up the process of consistency evaluation.
Judging from the current speed of national centralized procurement, it far exceeds industry expectations.
In the future, the national centralized procurement will involve more varieties of generic drugs through consistent evaluation.
In this process, those companies that have been reviewed with too many varieties, and the remaining companies that have not been reviewed may choose to abandon the market.
At the same time, some companies that are late to market and have weaker capital capabilities may also choose to give up the consistency evaluation.
Speed up the process of consistency evaluation.
Judging from the current speed of national centralized procurement, it far exceeds industry expectations.
In the future, the national centralized procurement will involve more varieties of generic drugs through consistent evaluation.
In this process, those companies that have been reviewed with too many varieties, and the remaining companies that have not been reviewed may choose to abandon the market.
At the same time, some companies that are late to market and have weaker capital capabilities may also choose to give up the consistency evaluation.
